BioSig Technologies, Inc. (BSGM)
$1.08
Rating:
Recommendation:
-
| Symbol | BSGM |
|---|---|
| Price | $1.08 |
| Beta | 1.234 |
| Volume Avg. | 0.35M |
| Market Cap | 63.307M |
| Shares () | - |
| 52 Week Range | 0.251-1.728 |
| 1y Target Est | - |
| DCF Unlevered | BSGM DCF -> | |
|---|---|---|
| DCF Levered | BSGM LDCF -> | |
| ROE | -374.02% | Strong Sell |
| ROA | -573.04% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 159.63% | Buy |
| P/E | - | |
| P/B | 25.23 | Strong Buy |
Latest BSGM news
About
Download (Excel)BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.